Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00051051 | A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer | PHASE2 | COMPLETED | 168 | — | — | Dec 1, 2002 | May 1, 2005 | May 4, 2007 | 66 | United States, Belgium +7 |
| Name | Type | Description |
|---|---|---|
| CI-1033 | DRUG | - |
Inclusion Criteria: * Female, at least 18 years of age * Histologically confirmed diagnosis of breast cancer * Metastatic (Stage IV) disease * Progressive or recurrent disease following the most recent therapy * No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease ...